TY - JOUR
T1 - Loss of UGP2 in brain leads to a severe epileptic encephalopathy, emphasizing that bi-allelic isoform-specific start-loss mutations of essential genes can cause genetic diseases
AU - Perenthaler, Elena
AU - Nikoncuk, Anita
AU - Yousefi, Soheil
AU - Berdowski, Woutje M.
AU - Alsagob, Maysoon
AU - Capo, Ivan
AU - van der Linde, Herma C.
AU - van den Berg, Paul
AU - Jacobs, Edwin H.
AU - Putar, Darija
AU - Ghazvini, Mehrnaz
AU - Aronica, Eleonora
AU - van IJcken, Wilfred F.J.
AU - de Valk, Walter G.
AU - Medici-van den Herik, Evita
AU - van Slegtenhorst, Marjon
AU - Brick, Lauren
AU - Kozenko, Mariya
AU - Kohler, Jennefer N.
AU - Bernstein, Jonathan A.
AU - Monaghan, Kristin G.
AU - Begtrup, Amber
AU - Torene, Rebecca
AU - Al Futaisi, Amna
AU - Al Murshedi, Fathiya
AU - Mani, Renjith
AU - Al Azri, Faisal
AU - Kamsteeg, Erik Jan
AU - Mojarrad, Majid
AU - Eslahi, Atieh
AU - Khazaei, Zaynab
AU - Darmiyan, Fateme Massinaei
AU - Doosti, Mohammad
AU - Karimiani, Ehsan Ghayoor
AU - Vandrovcova, Jana
AU - Zafar, Faisal
AU - Rana, Nuzhat
AU - Kandaswamy, Krishna K.
AU - Hertecant, Jozef
AU - Bauer, Peter
AU - AlMuhaizea, Mohammed A.
AU - Salih, Mustafa A.
AU - Aldosary, Mazhor
AU - Almass, Rawan
AU - Al-Quait, Laila
AU - Qubbaj, Wafa
AU - Coskun, Serdar
AU - Alahmadi, Khaled O.
AU - Hamad, Muddathir H.A.
AU - Alwadaee, Salem
AU - Awartani, Khalid
AU - Dababo, Anas M.
AU - Almohanna, Futwan
AU - Colak, Dilek
AU - Dehghani, Mohammadreza
AU - Mehrjardi, Mohammad Yahya Vahidi
AU - Gunel, Murat
AU - Ercan-Sencicek, A. Gulhan
AU - Passi, Gouri Rao
AU - Cheema, Huma Arshad
AU - Efthymiou, Stephanie
AU - Houlden, Henry
AU - Bertoli-Avella, Aida M.
AU - Brooks, Alice S.
AU - Retterer, Kyle
AU - Maroofian, Reza
AU - Kaya, Namik
AU - van Ham, Tjakko J.
AU - Barakat, Tahsin Stefan
N1 - Funding Information:
We are indebted to the parents of the patients for their kind cooperation. We thank Virginie Verhoeven and Gerben Schaaf for critically reading our manuscript and Grazia Mancini for helpful discussions. We thank Gerben Schaaf for providing the LAMP2 antibody, and Eskeatnaf Mulugeta for bioinformatics advice. We would like to thank Reviewer 1 for proposing the name “Barakat-Perenthaler-syndrome of developmental epileptic encephalopathy” for this new disorder. DP was supported by an Erasmus + Traineeship Programme. MAS was supported by the King Saud University (RSP-2019/38). AGES was supported by the Yale Center for Mendelian Genomics (NIH Grant M#UM1HG006504-05). HH is supported by the Rosetree Trust, Ataxia UK, MSA Trust, Brain Research UK, Muscular Dystrophy UK, Muscular Dystrophy Association, Higher Education Commission of Pakistan, The MRC (MR/S01165X/1, MR/S005021/1, G0601943), Wellcome Trust (WT093205MA, WT104033AIA, Synaptopathies Strategic Award, 165908) and National Institute for Health Research University College London Hospitals Biomedical Research Centre. Families 5–8 were collected as part of the SYNaPS Study Group collaboration funded by The Wellcome Trust and strategic award (Synaptopathies) funding. Research for these families was conducted as part of the Queen Square Genomics group at University College London, supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. NK is supported by intramural funds provided by King Faisal Specialist Hospital and Research Center, the National Plan for Science, Technology and Innovation program under King Abdulaziz City for Science and Technology and the King Salman Center for Disability Research. TVH is supported by an Erasmus University Rotterdam (EUR) fellowship. TSB’s lab is supported by the Netherlands Organisation for Scientific Research (ZonMW Veni, Grant 91617021), a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation, an Erasmus MC Fellowship 2017 and Erasmus MC Human Disease Model Award 2018. TSB, IC and EA acknowledge support from COST action CA16118 that facilitated this collaboration.
Funding Information:
We are indebted to the parents of the patients for their kind cooperation. We thank Virginie Verhoeven and Gerben Schaaf for critically reading our manuscript and Grazia Mancini for helpful discussions. We thank Gerben Schaaf for providing the LAMP2 antibody, and Eskeatnaf Mulugeta for bioinformatics advice. We would like to thank Reviewer 1 for proposing the name “Barakat-Perenthaler-syndrome of developmental epileptic encephalopathy” for this new disorder. DP was supported by an Erasmus + Traineeship Programme. MAS was supported by the King Saud University (RSP-2019/38). AGES was supported by the Yale Center for Mendelian Genomics (NIH Grant M#UM1HG006504-05). HH is supported by the Rosetree Trust, Ataxia UK, MSA Trust, Brain Research UK, Muscular Dystrophy UK, Muscular Dystrophy Association, Higher Education Commission of Pakistan, The MRC (MR/S01165X/1, MR/S005021/1, G0601943), Wellcome Trust (WT093205MA, WT104033AIA, Synaptopathies Strategic Award, 165908) and National Institute for Health Research University College London Hospitals Biomedical Research Centre. Families 5–8 were collected as part of the SYNaPS Study Group collaboration funded by The Wellcome Trust and strategic award (Synaptopathies) funding. Research for these families was conducted as part of the Queen Square Genomics group at University College London, supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. NK is supported by intramural funds provided by King Faisal Specialist Hospital and Research Center, the National Plan for Science, Technology and Innovation program under King Abdulaziz City for Science and Technology and the King Salman Center for Disability Research. TVH is supported by an Erasmus University Rotterdam (EUR) fellowship. TSB’s lab is supported by the Netherlands Organisation for Scientific Research (ZonMW Veni, Grant 91617021), a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation, an Erasmus MC Fellowship 2017 and Erasmus MC Human Disease Model Award 2018. TSB, IC and EA acknowledge support from COST action CA16118 that facilitated this collaboration.
Publisher Copyright:
© 2019, The Author(s).
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Developmental and/or epileptic encephalopathies (DEEs) are a group of devastating genetic disorders, resulting in early-onset, therapy-resistant seizures and developmental delay. Here we report on 22 individuals from 15 families presenting with a severe form of intractable epilepsy, severe developmental delay, progressive microcephaly, visual disturbance and similar minor dysmorphisms. Whole exome sequencing identified a recurrent, homozygous variant (chr2:64083454A > G) in the essential UDP-glucose pyrophosphorylase (UGP2) gene in all probands. This rare variant results in a tolerable Met12Val missense change of the longer UGP2 protein isoform but causes a disruption of the start codon of the shorter isoform, which is predominant in brain. We show that the absence of the shorter isoform leads to a reduction of functional UGP2 enzyme in neural stem cells, leading to altered glycogen metabolism, upregulated unfolded protein response and premature neuronal differentiation, as modeled during pluripotent stem cell differentiation in vitro. In contrast, the complete lack of all UGP2 isoforms leads to differentiation defects in multiple lineages in human cells. Reduced expression of Ugp2a/Ugp2b in vivo in zebrafish mimics visual disturbance and mutant animals show a behavioral phenotype. Our study identifies a recurrent start codon mutation in UGP2 as a cause of a novel autosomal recessive DEE syndrome. Importantly, it also shows that isoform-specific start-loss mutations causing expression loss of a tissue-relevant isoform of an essential protein can cause a genetic disease, even when an organism-wide protein absence is incompatible with life. We provide additional examples where a similar disease mechanism applies.
AB - Developmental and/or epileptic encephalopathies (DEEs) are a group of devastating genetic disorders, resulting in early-onset, therapy-resistant seizures and developmental delay. Here we report on 22 individuals from 15 families presenting with a severe form of intractable epilepsy, severe developmental delay, progressive microcephaly, visual disturbance and similar minor dysmorphisms. Whole exome sequencing identified a recurrent, homozygous variant (chr2:64083454A > G) in the essential UDP-glucose pyrophosphorylase (UGP2) gene in all probands. This rare variant results in a tolerable Met12Val missense change of the longer UGP2 protein isoform but causes a disruption of the start codon of the shorter isoform, which is predominant in brain. We show that the absence of the shorter isoform leads to a reduction of functional UGP2 enzyme in neural stem cells, leading to altered glycogen metabolism, upregulated unfolded protein response and premature neuronal differentiation, as modeled during pluripotent stem cell differentiation in vitro. In contrast, the complete lack of all UGP2 isoforms leads to differentiation defects in multiple lineages in human cells. Reduced expression of Ugp2a/Ugp2b in vivo in zebrafish mimics visual disturbance and mutant animals show a behavioral phenotype. Our study identifies a recurrent start codon mutation in UGP2 as a cause of a novel autosomal recessive DEE syndrome. Importantly, it also shows that isoform-specific start-loss mutations causing expression loss of a tissue-relevant isoform of an essential protein can cause a genetic disease, even when an organism-wide protein absence is incompatible with life. We provide additional examples where a similar disease mechanism applies.
KW - ATG mutations
KW - Epileptic encephalopathy
KW - Essential gene
KW - Founder mutation
KW - Genetics
KW - Microcephaly
KW - Recurrent mutation
KW - Start-loss mutation
KW - UGP2
KW - Whole exome sequencing
UR - http://www.scopus.com/inward/record.url?scp=85076733845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076733845&partnerID=8YFLogxK
U2 - 10.1007/s00401-019-02109-6
DO - 10.1007/s00401-019-02109-6
M3 - Article
C2 - 31820119
AN - SCOPUS:85076733845
SN - 0001-6322
VL - 139
SP - 415
EP - 442
JO - Acta Neuropathologica
JF - Acta Neuropathologica
IS - 3
ER -